BIOMARKER:

ABCG2 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ABCG2 overexpression	Osteosarcoma	ABCG2 overexpression	Osteosarcoma	MAP Resistant: C3 – Early Trials MAP Resistant : C3	MAP Resistant: C3 – Early Trials MAP Resistant : C3
ABCG2 overexpression	Head and Neck Cancer	ABCG2 overexpression	Head and Neck Cancer	paclitaxel Resistant: C3 – Early Trials paclitaxel Resistant : C3	paclitaxel Resistant: C3 – Early Trials paclitaxel Resistant : C3
ABCG2 overexpression	Breast Cancer	ABCG2 overexpression	Breast Cancer	paclitaxel Resistant: D – Preclinical paclitaxel Resistant : D	paclitaxel Resistant: D – Preclinical paclitaxel Resistant : D
ABCG2 overexpression	Colorectal Cancer	ABCG2 overexpression	Colorectal Cancer	oxaliplatin Resistant: D – Preclinical oxaliplatin Resistant : D	oxaliplatin Resistant: D – Preclinical oxaliplatin Resistant : D
ABCG2 overexpression	Colorectal Cancer	ABCG2 overexpression	Colorectal Cancer	PF-05212384 Resistant: D – Preclinical PF-05212384 Resistant : D	PF-05212384 Resistant: D – Preclinical PF-05212384 Resistant : D
ABCG2 overexpression	Solid Tumor	ABCG2 overexpression	Solid Tumor	TP-3654 + IT-141 Sensitive: D – Preclinical TP-3654 + IT-141 Sensitive : D	TP-3654 + IT-141 Sensitive: D – Preclinical TP-3654 + IT-141 Sensitive : D
ABCG2 overexpression	Solid Tumor	ABCG2 overexpression	Solid Tumor	mitoxantrone + TP-3654 Sensitive: D – Preclinical mitoxantrone + TP-3654 Sensitive : D	mitoxantrone + TP-3654 Sensitive: D – Preclinical mitoxantrone + TP-3654 Sensitive : D
ABCG2 overexpression	Solid Tumor	ABCG2 overexpression	Solid Tumor	topotecan + TP-3654 Sensitive: D – Preclinical topotecan + TP-3654 Sensitive : D	topotecan + TP-3654 Sensitive: D – Preclinical topotecan + TP-3654 Sensitive : D